Please login to the form below

Not currently logged in
Email:
Password:

ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director

Thomas ClayBelgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires.

Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his father, Landon Clay.

He said: “I Am very honoured to be appointed as chairman of the board of ThromboGenics at a time when the company is starting to make excellent progress with its exciting pipeline of four novel therapies for treating diabetic eye disease.”

Clay is also vice-president of East Hill Management, a US-based investment company and serves as chairman and CEO of Golden Queen Mining and as a director of the Clay Mathematics Institute.

Patrik De Haes, chief executive officer of ThromboGenics, said: “I am delighted that Thomas has agreed to take on the role of chairman, his rich experience and deep understanding of ThromboGenics and life sciences in general will be invaluable for the company in achieving its objectives going forward.”

27th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics